Top

Published in:

10-07-2023 | Lymphedema | Review

Global impact of lymphedema on quality of life and society

Authors: Katrina M. Jaszkul, Kaveh Farrokhi, Valera Castanov, Kathryn Minkhorst, Erica Ai Li, Lauren Sano, Stephanie Kim, Stephen Keelan, Khalifa Al-Ghanim, Andrew Simpson

Published in: European Journal of Plastic Surgery | Issue 6/2023

Abstract

Lymphedema is a chronic disorder of the lymphatic system characterized by the accumulation of interstitial fluid in tissues. It affects millions of individuals worldwide, resulting in significant disability and morbidity. Despite its prevalence, it is often an underappreciated clinical entity. In this narrative review, we critically examined and synthesized currently available peer-reviewed literature on the global epidemiology, pathophysiology, and societal burden of lymphedema. Most patients have a secondary cause of lymphedema, such as lymphatic filariasis, mostly prevalent in Asia, South America, and Africa. A smaller proportion of lymphedema is secondary to malignancy or post-oncological treatment. Breast cancer, prostate cancer, cervical cancer, and melanoma are most often associated with causing lymphedema secondary to nodal involvement. Several tools have been developed to assess the effect of lymphedema on quality of life which can cause personal and financial impacts on those affected. Lymphedema is a globally prevalent but underappreciated disease in the developed and developing world. Lymphedema causes a significant burden on quality of life and financial stability to patients. Therefore, awareness among the healthcare team and patient education on prevention and minimizing morbidity are crucial.

Level of Evidence: Not gradable.

Warren AG, Brorson H, Borud LJ, Slavin SA (2007) Lymphedema: A comprehensive review. Ann Plast Surg 59(4):464–472. https://doi.org/10.1097/01.sap.0000257149.42922.7eCrossRefPubMed

Azhar SH, Lim HY, Tan BK, Angeli V (2020) The unresolved pathophysiology of lymphedema. Front Physiol 11:137. https://doi.org/10.3389/fphys.2020.00137CrossRefPubMedPubMedCentral

Rockson SG (2017) Lymphatic medicine: paradoxically and unnecessarily ignored. Lymphat Res Biol 15(4):315–316. https://doi.org/10.1089/lrb.2017.29033.srCrossRefPubMedPubMedCentral

Lazarides MK, Mani R (2012) Wound physicians: lymphedema is not a problem that will go away if ignored. Int J Low Extrem Wounds 11(1):3–4. https://doi.org/10.1177/1534734612438058CrossRefPubMed

Brice G et al (2002) Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet 39(7):478. https://doi.org/10.1136/jmg.39.7.478CrossRefPubMedPubMedCentral

Shankar RK, Backeljauw PF (2018) Current best practice in the management of Turner syndrome. Ther Adv Endocrinol Metab 9(1):33–40. https://doi.org/10.1177/2042018817746291CrossRefPubMed

Rockson SG (2018) Lymphedema after breast cancer treatment. N Engl J Med 379(20):1937–1944. https://doi.org/10.1056/NEJMcp1803290CrossRefPubMed

Bernas M, Thiadens SRJ, Smoot B, Armer JM, Stewart P, Granzow J (2018) Lymphedema following cancer therapy: overview and options. Clin Exp Metastasis 35(5–6):547–551. https://doi.org/10.1007/s10585-018-9899-5CrossRefPubMed

Bona AF, Ferreira KR, Carvalho RBDM, Thuler LCS, Bergmann A (2020) Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: A systematic review. Int J Gynecol Cancer 30(11):1697–1704. https://doi.org/10.1136/ijgc-2020-001682CrossRefPubMed

10.

Arié A, Yamamoto T (2020) Lymphedema secondary to melanoma treatments: diagnosis, evaluation, and treatments. Glob Health Med 2(4):227. https://doi.org/10.35772/ghm.2020.01022CrossRefPubMedPubMedCentral

11.

Hettrick H, Nof L, Ward S, Ecthernach J (2004) Incidence and prevalence of lymphedema in patients following burn injury: A five-year retrospective and three-month prospective study. Lymphat Res Biol 2(1):11–24. https://doi.org/10.1089/1539685041690472CrossRefPubMed

12.

Thomas C, Le JT, Benson E (2020) Managing lymphedema in fracture care: current concepts and treatment principles. J Am Acad Orthop Surg 28(18):737–741. https://doi.org/10.5435/JAAOS-D-19-00722CrossRefPubMed

13.

Negasa A, Dufera M (2021) Assessment of etiology of elephantiasis and its associated risk factors in Jeldu district, West Shoa, Ethiopia. J Trop Med 2021:1–8. https://doi.org/10.1155/2021/5551637CrossRef

14.

Velanovich V, Szymanski W (1999) Quality of life of breast cancer patients with lymphedema. Am J Surg 177(3):184–188. https://doi.org/10.1016/S0002-9610(99)00008-2CrossRefPubMed

15.

Buki LP et al (2021) ‘I never heard anything about it’: knowledge and psychosocial needs of Latina breast cancer survivors with lymphedema. Women’s Heal 17:1–11. https://doi.org/10.1177/17455065211002488CrossRef

16.

Committee Executive (2016) The diagnosis and treatment of peripheral lymphedema: 2016 consensus document of the International Society of Lymphology. Lymphology 49(4):170–184

17.

Sleigh BC, Manna B (2021) Lymphedema. StatPearls

18.

Stanton MC et al (2017) Measuring the physical and economic impact of filarial lymphoedema in Chikwawa district, Malawi: a case-control study. Infect Dis Poverty 6(1):28. https://doi.org/10.1186/s40249-017-0241-2CrossRefPubMedPubMedCentral

19.

Caprioli T et al (2020) Quantifying the socio-economic impact of leg lymphoedema on patient caregivers in a lymphatic filariasis and podoconiosis co-endemic district of Ethiopia. PLoS Negl Trop Dis 14(3):e0008058. https://doi.org/10.1371/journal.pntd.0008058CrossRefPubMedPubMedCentral

20.

Weiss R (2016) Cost of a lymphedema treatment mandate-10 years of experience in the Commonwealth of Virginia. Health Econ Rev 6(42):1–12. https://doi.org/10.1186/s13561-016-0117-3CrossRef

21.

Ramaiah KD, Kumar KNV, Ramu K, Pani SP, Das PK (1997) Functional impairment caused by lymphatic filariasis in rural areas of South India. Trop Med Int Health 2(9):832–838. https://doi.org/10.1046/j.1365-3156.1997.d01-406.xCrossRefPubMed

22.

Clements AE, Tierney BJ, Cohn DE, Straughn JM (2013) Is selective lymphadenectomy more cost-effective than routine lymphadenectomy in patients with endometrial cancer? Gynecol Oncol 128(2):166–170. https://doi.org/10.1016/j.ygyno.2012.10.007CrossRefPubMed

23.

Földi M, Földi E, Strößenreuther C, Kubik S (2012) Földi’s textbook of lymphology: for physicians and lymphedema therapists. Elsevier Health Sciences

24.

Harel L, Amir J, Nussinovitch M, Straussberg R, Varsano I (1997) Lymphedema praecox seen as isolated unilateral arm involvement: case report and review of the literature. J Pediatr 130(3):492–494. https://doi.org/10.1016/s0022-3476(97)70219-1CrossRefPubMed

25.

Ferrell RE, Kimak MA, Lawrence EC, Finegold DN (2008) Candidate gene analysis in primary lymphedema. Lymphat Res Biol 6(2):69–76. https://doi.org/10.1089/lrb.2007.1022CrossRefPubMed

26.

Liu NF, Yan ZX, Wu XF (2012) Classification of lymphatic-system malformations in primary lymphoedema based on MR lymphangiography. Eur J Vasc Endovasc Surg 44(3):345. https://doi.org/10.1016/j.ejvs.2012.06.019CrossRefPubMed

27.

Rockson SG, Rivera KK (2008) Estimating the population burden of lymphedema. Ann N Y Acad Sci 1131:147–154. https://doi.org/10.1196/annals.1413.014CrossRefPubMed

28.

Rockson SG (2013) Chapter 58 - diseases of the lymphatic circulation. Vascular Medicine: A Companion to Braunworld's Heart Disease 3:697–708. https://doi.org/10.1016/B978-1-4377-2930-6.00058-6

29.

Specht S, Suma TK, Pedrique B, Hoerauf A (2019) Elimination of lymphatic filariasis in South East Asia. BMJ 364:k5198. https://doi.org/10.1136/bmj.k5198CrossRefPubMedPubMedCentral

30.

Nutman TB (2013) Insights into the pathogenesis of disease in human lymphatic filariasis. Lymphat Res Biol 11(3):144–148. https://doi.org/10.1089/lrb.2013.0021CrossRefPubMedPubMedCentral

31.

Lourens GB, Ferrell DK (2019) Lymphatic filariasis. Nurs Clin North Am 54(2):181–192. https://doi.org/10.1016/j.cnur.2019.02.007CrossRefPubMed

32.

Macfarlane CL, Budhathoki SS, Johnson S, Richardson M (2019) Garner P (2019) Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis. Cochrane Database Syst Rev 1:1–101. https://doi.org/10.1002/14651858.CD003753.pub4CrossRef

33.

Khieu V et al (2018) How elimination of lymphatic filariasis as a public health problem in the Kingdom of Cambodia was achieved. Infect Dis Poverty 7(15):1–9. https://doi.org/10.1186/s40249-018-0394-7CrossRef

34.

Ramzy RMR, Kamal HA, Hassan MA, Haggag AA (2019) Elimination of lymphatic filariasis as a public health problem from the Arab Republic of Egypt. Acta Trop 199:1–10. https://doi.org/10.1016/j.actatropica.2019.105121CrossRef

35.

Rahman MA et al (2019) A surveillance system for lymphatic filariasis after its elimination in Sri Lanka. Parasitol Int 68(1):73–78. https://doi.org/10.1016/j.parint.2018.10.003CrossRefPubMed

36.

Rojanapanus S et al (2019) How Thailand eliminated lymphatic filariasis as a public health problem. Infect Dis Poverty 8(38):1–15. https://doi.org/10.1186/s40249-019-0549-1CrossRef

37.

Yakob B, Deribe K, Davey G (2008) High levels of misconceptions and stigma in a community highly endemic for podoconiosis in southern Ethiopia. Trans R Soc Trop Med Hyg 102(5):439–444. https://doi.org/10.1016/j.trstmh.2008.01.023CrossRefPubMed

38.

Bartlett J et al (2016) Depression and disability in people with podoconiosis: a comparative cross-sectional study in rural Northern Ethiopia. Int Health 8(2):124–131. https://doi.org/10.1093/inthealth/ihv037CrossRefPubMed

39.

Phillips C, Samuel A, Tiruneh G, Deribe K, Davey G (2019) The impact of acute adenolymphangitis in podoconiosis on caregivers: A case study in Wayu Tuka woreda, Oromia, Western Ethiopia. ‘If she was healthy, I would be free. PLoS Negl Trop Dis 13(7):e0007487. https://doi.org/10.1371/journal.pntd.0007487CrossRefPubMedPubMedCentral

40.

Mousley E, Deribe K, Tamiru A, Davey G (2013) The impact of podoconiosis on quality of life in Northern Ethiopia. Health Qual Life Outcomes 11:122. https://doi.org/10.1186/1477-7525-11-122CrossRefPubMedPubMedCentral

41.

Yimer M, Hailu T, Mulu W, Abera B (2015) Epidemiology of elephantiasis with special emphasis on podoconiosis in Ethiopia: A literature review. J Vector Borne Dis 52(2):111–115PubMed

42.

Chandler DJ, Grijsen ML, Fuller LC (2021) With bare feet in the soil: podoconiosis, a neglected cause of tropical lymphoedema. Dermatology 237(2):236–247. https://doi.org/10.1159/000506045CrossRefPubMed

43.

Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM (2010) Lymphedema beyond breast cancer. Cancer 116(22):5138–5149. https://doi.org/10.1002/cncr.25458CrossRefPubMed

44.

Lopez M, Roberson ML, Strassle PD, Ogunleye A (2020) Epidemiology of Lymphedema-related admissions in the United States: 2012–2017. Surg Oncol 35:249–253. https://doi.org/10.1016/j.suronc.2020.09.005CrossRefPubMed

45.

DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515. https://doi.org/10.1016/S1470-2045(13)70076-7CrossRefPubMed

46.

Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GKD, Scott-Conner C (2009) The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol 16(7):1959–1972. https://doi.org/10.1245/s10434-009-0452-2CrossRefPubMed

47.

Keelan S et al (2021) Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis. Breast Cancer Res Treat 187(2):303–310. https://doi.org/10.1007/s10549-021-06194-8CrossRefPubMed

48.

Krag DN et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927–933. https://doi.org/10.1016/S1470-2045(10)70207-2CrossRefPubMedPubMedCentral

49.

Swenson KK, Nissen MJ, Ceronsky C, Swenson L, Lee MW, Tuttle TM (2002) Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol 9(8):745–753. https://doi.org/10.1007/BF02574496CrossRefPubMed

50.

Hyngstrom JR et al (2013) Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res 23(4):290–297. https://doi.org/10.1097/CMR.0b013e3283632c83CrossRefPubMed

51.

Treves N (1957) An evaluation of the etiological factors of lymphedema following radical mastectomy. An analysis of 1,007 cases. Cancer 10(3):444–459. https://doi.org/10.1002/1097-0142(195705/06)10:3%3c444::AID-CNCR2820100306%3e3.0.CO;2-7CrossRefPubMed

52.

McLaughlin SA et al (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26(32):5213–5219. https://doi.org/10.1200/JCO.2008.16.3725CrossRefPubMedPubMedCentral

53.

Werner RS et al (1991) Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology 180(1):177–184. https://doi.org/10.1148/radiology.180.1.2052688CrossRefPubMed

54.

Helyer LK, Varnic M, Le LW, Leong W, McCready D (2010) Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J 16(1):48–54. https://doi.org/10.1111/j.1524-4741.2009.00855.xCrossRefPubMed

55.

Ridner SH, Dietrich MS, Stewart BR, Armer JM (2011) Body mass index and breast cancer treatment-related lymphedema. Support Care Cancer 19(6):853–857. https://doi.org/10.1007/s00520-011-1089-9CrossRefPubMedPubMedCentral

56.

Petrek JA, Senie RT, Peters M, Rosen PP (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92(6):1368–1377. https://doi.org/10.1002/1097-0142(20010915)92:6%3c1368::aid-cncr1459%3e3.0.co;2-9CrossRefPubMed

57.

Kocak Z, Overgaard J (2000) Risk factors of arm lymphedema in breast cancer patients. Acta Oncol 39(3):389–392. https://doi.org/10.1080/028418600750013168CrossRefPubMed

58.

Ugur S et al (2013) Risk factors of breast cancer-related lymphedema. Lymphat Res Biol 11(2):72–75. https://doi.org/10.1089/lrb.2013.0004CrossRefPubMedPubMedCentral

59.

Guliyeva G, Huayllani MT, Boczar D, Avila FR, Lu X, Forte AJ (2021) Age as a risk factor for breast cancer-related lymphedema: a systematic review. J Cancer Surviv. https://doi.org/10.1007/s11764-021-00994-zCrossRefPubMed

60.

Grada AA, Phillips TJ (2017) Lymphedema: diagnostic workup and management. J Am Acad Dermatol 77(6):995–1006. https://doi.org/10.1016/j.jaad.2017.03.021CrossRefPubMed

61.

Oropallo A, Donis-Garcia M, Ahn S, Rao A (2020) Current concepts in the diagnosis and management of lymphedema. Adv Skin Wound Care 33(11):570–580. https://doi.org/10.1097/01.ASW.0000717220.39931.7aCrossRefPubMed

62.

Bittar S, Simman R, Lurie F (2020) Lymphedema: a practical approach and clinical update. Wounds 32(3):86–92PubMed

63.

Goss JA, Greene AK (2019) Sensitivity and specificity of the stemmer sign for lymphedema: a clinical lymphoscintigraphic study. Plast Reconstr Surg Glob Open 7(6):e2295. https://doi.org/10.1097/GOX.0000000000002295CrossRefPubMedPubMedCentral

64.

Dayan JH, Ly CL, Kataru RP, Mehrara BJ (2018) Lymphedema: pathogenesis and novel therapies. Annu Rev Med 69:263–273. https://doi.org/10.1146/annurev-med-060116-022900CrossRefPubMed

65.

Greene AK, Goss JA (2018) Diagnosis and staging of lymphedema. Semin Plast Surg 32(1):12–16. https://doi.org/10.1055/s-0038-1635117CrossRefPubMedPubMedCentral

66.

International Society of Lymphology (2013) The diagnosis and treatment of peripheral lymphedema: 2013 Consensus document of the international society of lymphology. Lymphology 46:1–11

67.

Vercruyce M, Debbaut C, Segers P (2021) The biochemical properties of the lymphatic system and the changes in lymphedema. Ghent University, Ghent

68.

Szuba A, Rockson SG (1998) Lymphedema: classification, diagnosis and therapy. Vasc Med 3(2):145–156. https://doi.org/10.1177/1358836x9800300209CrossRefPubMed

69.

Maclellan RA, Couto RA, Sullivan JE, Grant FD, Slavin SA, Greene AK (2015) Management of primary and secondary lymphedema: analysis of 225 referrals to a center. Ann Plast Surg 75(2):197–200. https://doi.org/10.1097/SAP.0000000000000022CrossRefPubMed

70.

Ridner SH et al (2019) A Randomized trial evaluating bioimpedance spectroscopy versus tape measurement for the prevention of lymphedema following treatment for breast cancer: interim analysis. Ann Surg Oncol 26(10):3250–3259. https://doi.org/10.1245/s10434-019-07344-5CrossRefPubMedPubMedCentral

71.

Lahtinen T, Seppälä J, Viren T, Johansson K (2015) Experimental and analytical comparisons of tissue dielectric constant (TDC) and bioimpedance spectroscopy (BIS) in assessment of early arm lymphedema in breast cancer patients after axillary surgery and radiotherapy. Lymphat Res Biol 13(3):176–185. https://doi.org/10.1089/lrb.2015.0019CrossRefPubMed

72.

Bundred NJ et al (2015) Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancer. Breast Cancer Res Treat 151(1):121–129. https://doi.org/10.1007/s10549-015-3357-8CrossRefPubMed

73.

Barrio AV, Eaton A, Frazier TG (2015) A Prospective validation study of bioimpedance with volume displacement in early-stage breast cancer patients at risk for lymphedema. Ann Surg Oncol 22:370–375. https://doi.org/10.1245/s10434-015-4683-0CrossRefPubMedCentral

74.

Pereira de Godoy JM, Guerreiro de Godoy MF (2010) Godoy & Godoy technique in the treatment of lymphedema for under-privileged populations. Int J Med Sci 7(2):68–71. https://doi.org/10.7150/ijms.7.68CrossRef

75.

Fish ML, Grover R, Schwarz GS (2020) Quality-of-life outcomes in surgical vs nonsurgical treatment of breast cancer-related lymphedema: A systematic review. JAMA Surg 155(6):513. https://doi.org/10.1001/jamasurg.2020.0230CrossRefPubMed

76.

Chang DW, Masia J 3rd, Garza R, Skoracki R, Neligan PC (2016) Lymphedema: surgical and medical therapy. Plast Reconstr Surg 138(3 Suppl):209S-218S. https://doi.org/10.1097/PRS.0000000000002683CrossRefPubMed

77.

Zasadzka E, Trzmiel T, Kleczewska M, Pawlaczyk M (2018) Comparison of the effectiveness of complex decongestive therapy and compression bandaging as a method of treatment of lymphedema in the elderly. Clin Interv Aging 13:929–934. https://doi.org/10.2147/CIA.S159380CrossRefPubMedPubMedCentral

78.

Bondalevich L, de Laplante S (2020) A 61-year-old woman with chronic leg lymphedema managed with complete decongestive therapy. CMAJ 192(26):E708–E712. https://doi.org/10.1503/cmaj.190227CrossRefPubMedPubMedCentral

79.

Executive Committee of the International Society of Lymphology (2020) The diagnosis and treatment of peripheral lymphedema: 2020 consensus document of the international society of lymphology. Lymphology 53(1):3–19. https://doi.org/10.2458/lymph.4649CrossRef

80.

Korpan MI, Crevenna R, Fialka-Moser V (2011) Lymphedema: A therapeutic approach in the treatment and rehabilitation of cancer patients. Am J Phys Med Rehabil 90(5):S69–S75. https://doi.org/10.1097/PHM.0b013e31820be160CrossRefPubMed

81.

Watanabe et al (2019) Development and themes of diagnostic and treatment procedures for secondary leg lymphedema in patients with gynecologic cancers. Healthcare 7(3):101. https://doi.org/10.3390/healthcare7030101CrossRefPubMedPubMedCentral

82.

Wanchai A, Beck M, Stewart BR, Armer JM (2013) Management of lymphedema for cancer patients with complex needs. Semin Oncol Nurs 29(1):61–65. https://doi.org/10.1016/j.soncn.2012.12.001CrossRefPubMed

83.

Williams A (2010) Manual lymphatic drainage: exploring the history and evidence base. Br J Community Nurs 15(3):S18-S24. https://doi.org/10.12968/bjcn.2010.15.sup3.47365

84.

Zimmermann A, Wozniewski M, Szklarska A, Lipowicz A, Szuba A (2012) Efficacy of manual lymphatic drainage in preventing secondary lymphedema after breast cancer surgery. Lymphology 45(3):103–112PubMed

85.

Tunkel RS, Lachmann E (1998) Lymphedema of the limb: An overview of treatment options. Postgrad Med 104(4):131–144. https://doi.org/10.3810/pgm.1998.10.450CrossRefPubMed

86.

Weil GJ et al (2019) The safety of double-and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLoS Med 16(6):e1002839. https://doi.org/10.1371/journal.pmed.1002839CrossRefPubMedPubMedCentral

87.

Mendoza N, Li A, Gill A, Tyring S (2009) Filariasis: diagnosis and treatment. Dermatol Ther 22(6):475–490. https://doi.org/10.1111/j.1529-8019.2009.01271.xCrossRefPubMed

88.

Kwan ML, Cohn JC, Armer JM, Stewart BR, Cormier JN (2011) Exercise in patients with lymphedema: a systematic review of the contemporary literature. J Cancer Surviv 5(4):320–336. https://doi.org/10.1007/s11764-011-0203-9CrossRefPubMed

89.

Park KE et al (2020) Surgical management of lymphedema: a review of current literature. Gland Surg 9(2):503–511. https://doi.org/10.21037/gs.2020.03.14CrossRefPubMedPubMedCentral

90.

Merchant SJ, Chen SL (2015) Prevention and management of lymphedema after breast cancer treatment. Breast J 21(3):276–284. https://doi.org/10.1111/tbj.12391CrossRefPubMed

91.

Chang EI, Skoracki RJ, Chang DW (2018) Lymphovenous anastomosis bypass surgery. Semin Plast Surg 32(1):22–27. https://doi.org/10.1055/s-0038-1636510CrossRefPubMedPubMedCentral

92.

Hanson SE, Chang EI, Schaverien MV, Chu C, Selber JC, Hanasono MM (2020) Controversies in surgical management of lymphedema. Plast Reconstr Surg Glob Open 8(3):e2671. https://doi.org/10.1097/GOX.0000000000002671CrossRefPubMedPubMedCentral

93.

He L, Qu H, Wu Q, Song Y (2020) Lymphedema in survivors of breast cancer (Review). Oncol Lett 19(3):2085–2096. https://doi.org/10.3892/ol.2020.11307CrossRefPubMedPubMedCentral

94.

Ezawa M et al (2019) Long term outcomes from lymphatic venous anastomosis after total hysterectomy to prevent postoperative lymphedema in lower limb. BMC Surg 19(177):1–6. https://doi.org/10.1186/s12893-019-0628-zCrossRef

95.

Dionyssiou D, Sarafis A, Tsimponis A, Kalaitzoglou A, Arsos G, Demiri E (2021) Long-term outcomes of lymph node transfer in secondary lymphedema and its correlation with flap characteristics. Cancers (Basel) 13(24):6198. https://doi.org/10.3390/cancers13246198CrossRefPubMed

96.

Raju A, Chang DW (2015) Vascularized lymph node transfer for treatment of lymphedema: a comprehensive literature review. Ann Surg 261(5):1013–1023. https://doi.org/10.1097/SLA.0000000000000763CrossRefPubMed

97.

Chu CK, Schaverien MV, Chang EI, Hanson SE, Hanasono MM, Selber JC (2020) Intra-Abdominal lymph nodes: a privileged donor site for vascularized lymph node transfer. Plast Reconstr Surg Glob Open 8(3):e2673. https://doi.org/10.1097/GOX.0000000000002673CrossRefPubMedPubMedCentral

98.

Brorson H (2012) From lymph to fat: Liposuction as a treatment for complete reduction of lymphedema. Int J Low Extrem Wounds 11(1):10–19. https://doi.org/10.1177/1534734612438550CrossRefPubMed

99.

Blome C et al (2014) Evaluation of patient-relevant outcomes of lymphedema and lipedema treatment: development and validation of a new benefit tool. Eur J Vasc Endovasc Surg 47(1):100–107. https://doi.org/10.1016/j.ejvs.2013.10.009CrossRefPubMed

100.

Ridner SH, Dietrich MS (2015) Development and validation of the lymphedema symptom and intensity survey-arm. Support Care Cancer 23(10):3103–3112. https://doi.org/10.1007/s00520-015-2684-yCrossRefPubMedPubMedCentral

101.

Keeley V, Crooks S, Locke J, Veigas D, Riches K, Hilliam R (2010) A quality of life measure for limb lymphoedema (LYMQOL). J Lymphoedema 5:26–37

102.

Devoogdt N, Van Kampen M, Geraerts I, Coremans T, Christiaens M-R (2011) Lymphoedema functioning, disability and health questionnaire (Lymph-ICF): reliability and validity. Phys Ther 91(6):944–957. https://doi.org/10.2522/ptj.20100087CrossRefPubMed

103.

Cornelissen AJM et al (2018) Quality of life questionnaires in breast cancer-related lymphedema patients: review of the literature. Lymphat Res Biol 16(2):134–139. https://doi.org/10.1089/lrb.2017.0046CrossRefPubMed

104.

Klernäs P, Johnsson A, Horstmann V, Kristjanson L, Johansson K (2015) Lymphedema quality of life inventory (LyQLI)-development and investigation of validity and reliability. Qual Life Res 24(2):427–439. https://doi.org/10.1007/s11136-014-0783-8CrossRefPubMed

105.

van de Pas CB, Biemans AAM, Boonen RSM, Viehoff PB, Neumann HAM (2016) Validation of the lymphoedema quality-of-life questionnaire (LYMQOL) in Dutch patients diagnosed with lymphoedema of the lower limbs. Phlebology 31(4):257–263. https://doi.org/10.1177/0268355515586312CrossRefPubMed

106.

Wedin M et al (2020) Validation of the lymphoedema quality of life questionnaire (LYMQOL) in Swedish cancer patients. Acta Oncol (Madr) 59(3):365–371. https://doi.org/10.1080/0284186X.2019.1701199CrossRef

107.

Monticone M et al (2021) Lymphedema quality of life questionnaire (LYMQOL): cross-cultural adaptation and validation in Italian women with upper limb lymphedema after breast cancer. Disabil Rehabil 35(2):1–6. https://doi.org/10.1080/09638288.2021.1890842CrossRef

108.

Mercier G, Pastor J, Moffatt C, Franks P, Quéré I (2019) LIMPRINT: health-related quality of life in adult patients with chronic edema. Lymphat Res Biol 17(2):163–167. https://doi.org/10.1089/lrb.2018.0084CrossRefPubMedPubMedCentral

109.

Jørgensen MG, Toyserkani NM, Hansen FG, Bygum A, Sørensen JA (2021) The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment. NPJ Breast Cancer 7(1):70. https://doi.org/10.1038/s41523-021-00276-yCrossRefPubMedPubMedCentral

110.

Thomas C et al (2014) Comparison of three quality of life instruments in lymphatic filariasis: DLQI, WHODAS 2.0, and LFSQQ. PLoS Negl Trop Dis 8(2):e2716–e2716. https://doi.org/10.1371/journal.pntd.0002716CrossRefPubMedPubMedCentral

111.

Narahari SR et al (2013) Community level morbidity control of lymphoedema using self care and integrative treatment in two lymphatic filariasis endemic districts of South India: a non randomized interventional study. Trans R Soc Trop Med Hyg 107(9):566–577. https://doi.org/10.1093/trstmh/trt054CrossRefPubMed

112.

Obindo J et al (2017) Prevalence of depression and associated clinical and socio-demographic factors in people living with lymphatic filariasis in Plateau State, Nigeria. PLoS Negl Trop Dis 11(6):e0005567

113.

Ali O et al (2020) A cross-sectional study to evaluate depression and quality of life among patients with lymphoedema due to podoconiosis, lymphatic filariasis and leprosy. Trans R Soc Trop Med Hyg 114(12):983–994. https://doi.org/10.1093/trstmh/traa130CrossRefPubMedPubMedCentral

114.

Asiedu SO, Kwarteng A, Amewu EKA, Kini P, Aglomasa BC, Forkuor JB (2021) Financial burden impact quality of life among lymphatic Filariasis patients. BMC Public Health 21(1):174. https://doi.org/10.1186/s12889-021-10170-8CrossRefPubMedPubMedCentral

115.

Semrau M et al (2020) EnDPoINT: protocol for an implementation research study to integrate a holistic package of physical health, mental health and psychosocial care for podoconiosis, lymphatic filariasis and leprosy into routine health services in Ethiopia. BMJ Open 10(10):e037675. https://doi.org/10.1136/bmjopen-2020-037675CrossRefPubMedPubMedCentral

116.

Zeldenryk L, Gray M, Gordon S, Speare R, Hossain M (2014) The use of focus groups to develop a culturally relevant quality of life tool for lymphatic filariasis in Bangladesh. Qual Life Res 23(1):299–309. https://doi.org/10.1007/s11136-013-0455-0CrossRefPubMed

117.

van ’t Noordende AT, Aycheh MW, Schippers A (2020) The impact of leprosy, podoconiosis and lymphatic filariasis on family quality of life: a qualitative study in Northwest Ethiopia. PLoS Negl Trop Dis 14(3):e0008173. https://doi.org/10.1371/journal.pntd.0008173CrossRef

118.

Keast DH, Moffatt C, Janmohammad A (2019) Lymphedema impact and prevalence international study: the canadian data. Lymphat Res Biol 17(2):178–186. https://doi.org/10.1089/lrb.2019.0014CrossRefPubMedPubMedCentral

119.

Huggenberger K, Wagner S, Lehmann S, Aeschlimann A, Amann-Vesti B, Angst F (2015) Health and quality of life in patients with primary and secondary lymphedema of the lower extremity. Vasa 44(2):129–137. https://doi.org/10.1024/0301-1526/A000419CrossRefPubMed

120.

Herberger K, Blome C, Heyer K, Ellis F, Münter KC, Augustin M (2017) Quality of life in patients with primary and secondary lymphedema in the community. Wound Repair Regen 25(3):466–473. https://doi.org/10.1111/wrr.12529CrossRefPubMed

121.

Okajima S et al (2013) Health-related quality of life and associated factors in patients with primary lymphedema. Jpn J Nurs Sci 10(2):202–211. https://doi.org/10.1111/J.1742-7924.2012.00220.XCrossRefPubMed

122.

Cheng M-H, Liu TT-F (2020) Lymphedema microsurgery improved outcomes of pediatric primary extremity lymphedema. Microsurgery 40(7):766–775. https://doi.org/10.1002/MICR.30622CrossRefPubMed

123.

Schook CC, Mulliken JB, Fishman SJ, Grant FD, Zurakowski D, Greene AK (2011) Primary lymphedema: clinical features and management in 138 pediatric patients. Plast Reconstr Surg 127(6):2419–2431. https://doi.org/10.1097/PRS.0B013E318213A218CrossRefPubMed

124.

Taghian NR, Miller CL, Jammallo LS, O’Toole J, Skolny MN (2014) Lymphedema following breast cancer treatment and impact on quality of life: a review. Crit Rev Oncol Hematol 92(3):227–234. https://doi.org/10.1016/j.critrevonc.2014.06.004CrossRefPubMed

125.

Ahmed RL, Prizment A, Lazovich DA, Schmitz KH, Folsom AR (2008) Lymphedema and quality of life in breast cancer survivors: The Iowa Women’s Heal Study. J Clin Oncol 26(35):5689–5696. https://doi.org/10.1200/JCO.2008.16.4731CrossRefPubMedPubMedCentral

126.

Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG (2018) Breast cancer-related lymphedema: Risk factors, precautionary measures, and treatments. Gland Surg 7(4):379–403. https://doi.org/10.21037/gs.2017.11.04CrossRefPubMedPubMedCentral

127.

Acebedo JC, Haas BK, Hermanns M (2021) Breast cancer-related lymphedema in hispanic women: a phenomenological study. J Transcult Nurs 32(1):41–49. https://doi.org/10.1177/1043659619891236CrossRefPubMed

128.

Ridner SH, Bonner CM, Deng J, Sinclair VG (2012) Voices from the shadows: Living with lymphedema. Cancer Nurs 35(1):E18–E26. https://doi.org/10.1097/NCC.0b013e31821404c0CrossRefPubMedPubMedCentral

129.

Teo I, Novy DM, Chang DW, Cox MG, Fingeret MC (2015) Examining pain, body image, and depressive symptoms in patients with lymphedema secondary to breast cancer. Psychooncology 24(11):1377–1383. https://doi.org/10.1002/pon.3745CrossRefPubMed

130.

Boing L et al (2019) Factors associated with depression symptoms in women after breast cancer. Rev Saude Publica 53:30. https://doi.org/10.11606/S1518-8787.2019053000786CrossRefPubMedPubMedCentral

131.

Dominick SA, Natarajan L, Pierce JP, Madanat H, Madlensky L (2014) The psychosocial impact of lymphedema-related distress among breast cancer survivors in the WHEL Study. Psychooncology 23(9):1049–1056. https://doi.org/10.1002/pon.3510CrossRefPubMedPubMedCentral

132.

Rockson SG, Keeley V, Kilbreath S, Szuba A, Towers A (2019) Cancer-associated secondary lymphoedema. Nat Rev Dis Primers 5(1):16. https://doi.org/10.1038/s41572-019-0072-5CrossRef

133.

Sun Y, Shigaki CL, Armer JM (2017) Return to work among breast cancer survivors: A literature review. Support Care Cancer 25(3):709–718. https://doi.org/10.1007/s00520-016-3446-1CrossRefPubMed

134.

Fantoni SQ, Peugniez C, Duhamel A, Skrzypczak J, Frimat P, Leroyer A (2010) Factors related to return to work by women with breast cancer in northern France. J Occup Rehabil 20(1):49–58. https://doi.org/10.1007/s10926-009-9215-yCrossRefPubMed

135.

Beesley V, Janda M, Eakin E, Obermair A, Battistutta D (2007) Lymphedema after gynecological cancer treatment : prevalence, correlates, and supportive care needs. Cancer 109(12):2607–2614. https://doi.org/10.1002/cncr.22684CrossRefPubMed

136.

Dunberger G, Lindquist H, Waldenström AC, Nyberg T, Steineck G, Åvall-Lundqvist E (2013) Lower limb lymphedema in gynecological cancer survivors - Effect on daily life functioning. Support Care Cancer 21(11):3063–3070. https://doi.org/10.1007/s00520-013-1879-3CrossRefPubMed

137.

Franks PJ, Moffatt CJ, Doherty DC, Williams AF, Jeffs E, Mortimer PS (2006) Assessment of health-related quality of life in patients with lymphedema of the lower limb. Wound Repair Regen 14(2):110–118. https://doi.org/10.1111/j.1743-6109.2006.00099.xCrossRefPubMed

138.

Ryan M, Stainton MC, Jaconelli C, Watts S, MacKenzie P, Mansberg T (2003) The experience of lower limb lymphedema for women after treatment for gynecologic cancer. Oncol Nurs Forum 30(3):417–423. https://doi.org/10.1188/03.ONF.417-423CrossRefPubMed

139.

Finnane A, Hayes SC, Obermair A, Janda M (2011) Quality of life of women with lower-limb lymphedema following gynecological cancer. Expert Rev Pharmacoecon Outcomes Res 11(3):287–297. https://doi.org/10.1586/erp.11.30CrossRefPubMed

140.

Kim SI et al (2015) Impact of lower limb lymphedema on quality of life in gynecologic cancer survivors after pelvic lymph node dissection. Eur J Obstet Gynecol Reprod Biol 192:31–36. https://doi.org/10.1016/j.ejogrb.2015.06.011CrossRefPubMed

141.

Novackova M et al (2012) A prospective study in detection of lower-limb lymphedema and evaluation of quality of life after vulvar cancer surgery. Int J Gynecol Cancer 22(6):1081–1088. https://doi.org/10.1097/IGC.0b013e31825866d0CrossRefPubMed

142.

Suma TK, Shenoy RK, Kumaraswami V (2003) A qualitative study of the perceptions, practices and socio-psychological suffering related to chronic brugian filariasis in Kerala, southern India. Ann Trop Med Parasitol 97(8):839–845. https://doi.org/10.1179/000349803225002435CrossRefPubMed

143.

Person B et al (2007) A qualitative study of the psychosocial and health consequences associated with lymphedema among women in the Dominican Republic. Acta Trop 103(2):90–97. https://doi.org/10.1016/j.actatropica.2007.05.010CrossRefPubMed

144.

Dreyer G, Norões J, Addiss D (1997) The silent burden of sexual disability associated with lymphatic filariasis. Acta Trop 63(1):57–60. https://doi.org/10.1016/s0001-706x(96)00604-3CrossRefPubMed

145.

Stanton MC et al (2016) Situational analysis of lymphatic filariasis morbidity in Ahanta West District of Ghana. Trop Med Int Health 21(2):236–244. https://doi.org/10.1111/tmi.12643CrossRefPubMed

146.

Grada AA, Phillips TJ (2017) Lymphedema: pathophysiology and clinical manifestations. J Am Acad Dermatol 77(6):1009–1020. https://doi.org/10.1016/j.jaad.2017.03.022CrossRefPubMed

147.

Narahari SR, Ryan TJ, Bose KS, Prasanna KS, Aggithaya GM (2011) Integrating modern Dermatol Jand Ayurveda in the treatment of vitiligo and lymphedema in India. Int J Dermatol 50(3):310–334. https://doi.org/10.1111/j.1365-4632.2010.04744.xCrossRefPubMed

148.

Stout NL et al (2013) A systematic review of care delivery models and economic analyses in lymphedema: Health policy impact (2004–2011). Lymphology 46(1):27–41PubMed

149.

Shih YCT et al (2009) Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: A 2-year follow-up study. J Clin Oncol 27(12):2007–2014. https://doi.org/10.1200/JCO.2008.18.3517CrossRefPubMed

150.

Moffatt C, Keeley V, Quere I (2019) The concept of chronic edema-A neglected public health issue and an international response: The limprint study. Lymphat Res Biol 17(2):121–126. https://doi.org/10.1089/lrb.2018.0085CrossRefPubMedPubMedCentral

151.

Murdaca G et al (2012) Current views on diagnostic approach and treatment of lymphedema. Am J Med. 125(2):134–140. https://doi.org/10.1016/j.amjmed.2011.06.032CrossRefPubMed

152.

Babu BV, Nayak AN (2003) Treatment costs and work time loss due to episodic adenolymphangitis in lymphatic filariasis patients in rural communities of Orissa, India. Trop Med Int Health 8(12):1102–1109. https://doi.org/10.1046/j.1360-2276.2003.01146.xCrossRefPubMed

153.

Ramaiah KD, Ramu K, Guyatt H, Vijar Kumar KN, Pani SP (1998) Direct and indirect costs of the acute form of lymphatic filariasis to households in rural areas of tamil nadu, south india. Trop Med Int Health 3(2):108–115. https://doi.org/10.1046/j.1365-3156.1998.00208.xCrossRefPubMed

154.

Ramaiah KD, Guyatt H, Ramu K, Vanamail P, Pani SP, Das PK (1999) Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in south India. Trop Med Int Health 4(1):19–25. https://doi.org/10.1046/j.1365-3156.1999.00351.xCrossRefPubMed

155.

Lee JY et al (2014) The cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer: Insights from the US and Korean healthcare systems. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2014.09.020CrossRefPubMedPubMedCentral

156.

Suidan RS et al (2018) Three lymphadenectomy strategies in low-risk endometrial carcinoma a cost-effectiveness analysis. Obstet Gynecol 132(1):52–58. https://doi.org/10.1097/AOG.0000000000002677CrossRefPubMedPubMedCentral

157.

Mercier G, Pastor J, Clément V, Rodts U, Moffat C, Quéré I (2019) Out-of-pocket payments, vertical equity and unmet medical needs in France: A national multicenter prospective study on lymphedema. PLoS ONE 14(5):e0216386. https://doi.org/10.1371/journal.pone.0216386CrossRefPubMedPubMedCentral

158.

Sawers L, Stillwaggon E (2020) Economic costs and benefits of community-based lymphedema-management programs for lymphatic filariasis in India. Am J Trop Med Hyg 103(1):295–302. https://doi.org/10.4269/ajtmh.19-0898CrossRefPubMedPubMedCentral

159.

Hounsome N et al (2019) Cost-effectiveness and social outcomes of a community-based treatment for podoconiosis lymphoedema in the East Gojjam zone. Ethiopia. PLoS Negl Trop Dis 13(10):e0007780. https://doi.org/10.1371/journal.pntd.0007780CrossRefPubMed

160.

Tekola F, Mariam DH, Davey G (2006) Economic costs of endemic non-filarial elephantiasis in Wolaita Zone, Ethiopia. Trop Med Int Health 11(7):1136–1144. https://doi.org/10.1111/j.1365-3156.2006.01658.xCrossRefPubMed

Title: Global impact of lymphedema on quality of life and society
Authors: Katrina M. Jaszkul
Kaveh Farrokhi
Valera Castanov
Kathryn Minkhorst
Erica Ai Li
Lauren Sano
Stephanie Kim
Stephen Keelan
Khalifa Al-Ghanim
Andrew Simpson
Publication date: 10-07-2023
Publisher: Springer Berlin Heidelberg
Keyword: Lymphedema
Published in: European Journal of Plastic Surgery / Issue 6/2023
Print ISSN: 0930-343X
Electronic ISSN: 1435-0130
DOI: https://doi.org/10.1007/s00238-023-02094-w

2024 ASCO Annual Meeting

Springer Medicine

Global impact of lymphedema on quality of life and society

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2023

Analysis of complications following implant-based breast reconstruction in breast cancer patients

Soft tissue reconstruction of combat-related injuries affecting the lower limb: is a time target realistic? A systematic review and meta-analysis

Regenerative therapy for refractory vitiligo using cultured epithelial sheet grafting

Surgical choices and complications in elderly women: a single center retrospective analysis in frail vs. non frail breast cancer patients

Columellar incision in labiocolumellar junction

The use of a superficial circumflex iliac artery perforator flap obtained by a proximal to distal freestyle technique for the reconstruction of limb defects